Invitae Corp. (NVTA)

17.41
NYSE : Health Services
Prev Close 18.26
Day Low/High 16.86 / 18.16
52 Wk Low/High 9.04 / 28.75
Avg Volume 2.26M
Exchange NYSE
Shares Outstanding 95.18M
Market Cap 1.74B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Invitae Expands Detect Program To Offer No-Charge Genetic Testing To Pancreatic Cancer Patients

Invitae Expands Detect Program To Offer No-Charge Genetic Testing To Pancreatic Cancer Patients

- Professional guidelines recommend genetic testing for all pancreatic cancer patients -

Invitae Prices Upsized Offering Of $300 Million Of Convertible Senior Notes

Invitae Prices Upsized Offering Of $300 Million Of Convertible Senior Notes

SAN FRANCISCO, Sept. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) announced the pricing on September 5, 2019 of $300.

Invitae Announces Proposed Offering Of $200 Million Of Convertible Senior Notes

Invitae Announces Proposed Offering Of $200 Million Of Convertible Senior Notes

SAN FRANCISCO, Sept. 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.

Investing in Small Biotechs? Check Out the CFO First

Investing in Small Biotechs? Check Out the CFO First

They're the most important executive at most small developmental or early commercialization concerns.

Yes, the Market Hates Uncertainty

Yes, the Market Hates Uncertainty

If the macro issues calm down there should be some good trade opportunities.

A Weak Bounce Continues as Stock Picking Heats Up

A Weak Bounce Continues as Stock Picking Heats Up

The market action is creating some mis-pricing in individual stocks. But if the market stays under pressure then stock picking will remain difficult.

Invitae Reports $53.5 Million In Quarterly Revenue Driven By More Than 111,000 Samples In Quarterly Volume

Invitae Reports $53.5 Million In Quarterly Revenue Driven By More Than 111,000 Samples In Quarterly Volume

-- Increased quarterly revenue by 43% and volume by 52% year-over-year --

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.

Look on the Bright Side

We saw some minor positives in Thursday's decline, so let's dive into them and what they mean.

Short-Seller Left Goes Long on Invitae With $100 Target

Short-Seller Left Goes Long on Invitae With $100 Target

Citron analyst sees 'indestructible moat' around genetic-testing company's business.

Invitae Launches Detect Programs To Make It Easier For Patients To Get Genetic Testing For Prostate Cancer, Muscular Dystrophy And Heart Conditions

Invitae Launches Detect Programs To Make It Easier For Patients To Get Genetic Testing For Prostate Cancer, Muscular Dystrophy And Heart Conditions

- Designed to overcome barriers to testing and connect patients to earlier diagnosis and treatments -

Invitae To Announce Second Quarter 2019 Financial Results On August 6, 2019

Invitae To Announce Second Quarter 2019 Financial Results On August 6, 2019

SAN FRANCISCO, July 23, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call...

IBM and Netflix Go Separate Ways in Nervous Trading

IBM and Netflix Go Separate Ways in Nervous Trading

I don't expect to see the bears and shorts press too hard right now but there isn't going to be much upside momentum.

Invitae Shares Rise After Famed Short-Seller Andrew Left Goes Long the Stock

Invitae Shares Rise After Famed Short-Seller Andrew Left Goes Long the Stock

Biotech adds 4% to $23.44 after Left, who's better known for his short positions, argues it can go to $100 a share.

Invitae To Acquire Jungla To Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis To Deliver Deeper, More Informative Results To Patients

Invitae To Acquire Jungla To Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis To Deliver Deeper, More Informative Results To Patients

-- Jungla Applies Advanced Modeling Technologies, Including Artificial Intelligence, to Enhance Scalable Genetic Variant Interpretation --

First Week Of NVTA August 16th Options Trading

First Week Of NVTA August 16th Options Trading

Investors in Invitae Corp saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVTA options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Invitae Reports Inducement Grants Under NYSE Rule 303A.08 To Former Employees Of Singular Bio, Inc. In Connection With Closing Of Acquisition

Invitae Reports Inducement Grants Under NYSE Rule 303A.08 To Former Employees Of Singular Bio, Inc. In Connection With Closing Of Acquisition

SAN FRANCISCO, June 20, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted time-based and development milestone-based restricted stock units ("RSUs") to new employees who joined...

Noteworthy Wednesday Option Activity: NVTA, ETN, AMAG

Noteworthy Wednesday Option Activity: NVTA, ETN, AMAG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Invitae Corp , where a total volume of 6,067 contracts has been traded thus far today, a contract volume which is representative of approximately 606,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49.2% of NVTA's average daily trading volume over the past month, of 1.2 million shares.

Invitae To Acquire Singular Bio To Help Increase Access To Genetic Screening In Early Pregnancy

Invitae To Acquire Singular Bio To Help Increase Access To Genetic Screening In Early Pregnancy

-- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening --

X4 Pharmaceuticals And Invitae Announce Partnership To Provide No-Cost Genetic Testing To Patients Suspected Of Primary Immunodeficiency Disease

X4 Pharmaceuticals And Invitae Announce Partnership To Provide No-Cost Genetic Testing To Patients Suspected Of Primary Immunodeficiency Disease

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NYSE: NVTA), a leader in medical genetics, today announced a...

Invitae Announces ID YOUR IRD Program To Expand Access To Genetic Testing For Inherited Retinal Disorders

Invitae Announces ID YOUR IRD Program To Expand Access To Genetic Testing For Inherited Retinal Disorders

-Genetic testing can identify causes of rare, progressive eye disorders-

Invitae Introduces New Service To Make It Easier For Consumers To Receive The Medical Genetic Testing That Experts Trust

Invitae Introduces New Service To Make It Easier For Consumers To Receive The Medical Genetic Testing That Experts Trust

-- Provides high-quality, affordable, clinician-guided genetic testing to inform healthcare decisions --

Research From Invitae Demonstrates The Importance Of Germline Multigene Panel Testing In Guiding Therapy For Expanding Groups Of Cancer Patients

Research From Invitae Demonstrates The Importance Of Germline Multigene Panel Testing In Guiding Therapy For Expanding Groups Of Cancer Patients

- Data to be presented at the American Society of Clinical Oncology Annual Meeting -

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics Plc And Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to...

Invitae To Present At The 2019 William Blair Growth Stock Conference

Invitae To Present At The 2019 William Blair Growth Stock Conference

SAN FRANCISCO, May 22, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock...

Invitae To Present At The UBS Global Healthcare Conference

Invitae To Present At The UBS Global Healthcare Conference

SAN FRANCISCO, May 15, 2019 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare...

New Study From Invitae Highlights The Importance Of Multigene Genetic Testing For Uterine Cancer Patients

New Study From Invitae Highlights The Importance Of Multigene Genetic Testing For Uterine Cancer Patients

Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

NVTA December 20th Options Begin Trading

NVTA December 20th Options Begin Trading

Investors in Invitae Corp saw new options begin trading today, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)